Japanese CRO Mediscience Planning Launches IPO On Osaka Stock Market
This article was originally published in PharmAsia News
Japanese contract research organization Mediscience Planning launched its initial public offering Oct. 7 on the Osaka Stock Exchange. Japan's leading CRO, Mediscience Planning was established in 1982 and merged with CRO Comotech in 2005. As of August 2007, the company has ¥4.3 billion in sales and ¥160 million in net profit. (Click here for more - Japanese language
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.